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Abstract
Introduction: The treatment of mucosal leishmaniasis (ML) is difficult due to the toxicity and route of administration of standard 
drugs. Miltefosine is an oral agent used for leishmaniasis treatment; however, no data exist regarding its use for ML in Brazil. 
In this study, we aimed to evaluate the efficacy of miltefosine for ML treatment compared to that of pentavalent antimonial in 
a pilot study. Methods: We performed a randomized clinical trial with two parallel groups. The tested intervention consisted of 
miltefosine 1.3–2 mg/kg/day (two capsules) for 28 days or intravenous 20 mg SbV/kg/day of meglumine antimoniate (N-MA) 
for 30 days. The final endpoint was defined as complete healing of the lesion four years after treatment. We also analyzed an 
early endpoint at 90 days after treatment. Results: Forty patients were included in this study: each experimental group comprised 
20 patients. Applying a multivariate model in an intention-to-treat analysis, we observed that patients treated with miltefosine 
had a cure probability 2.08 times greater (95% confidence interval [CI] = 1.03–4.18) than those treated with N-MA at 90 days 
after treatment. At the final endpoint, we observed no differences in cure probability between miltefosine and N-MA (relative 
risk = 0.66; 95% CI = 0.33–1.32). With respect to adverse reactions, significant differences between groups were related to 
gastrointestinal effects, which were more frequent in the miltefosine group. Conclusions: Miltefosine may be an interesting 
alternative for treating ML because of its oral administration and cure rate after long-term follow-up.
Keywords: Leishmaniasis. Mucosal Leishmaniasis. Controlled clinical trial. Pentavalent antimonial. Therapeutics. Miltefosine.
INTRODUCTION
American tegumentary leishmaniasis (ATL) is increasing 
alarmingly in incidence1. The mucosal form is characterized 
by the resulting facial disfiguration2,3. ATL is generally caused 
by Leishmania (V.) braziliensis, although it may also be caused 
by Leishmania (V.) panamensis, Leishmania (V.) guyanensis or, 
rarely, by Leishmania (L.) amazonensis4-8. Previous studies have 
indicated that mucosal lesions develop six to 24 months after 
cutaneous leishmaniasis (CL), beginning as septal infiltration 
and ultimately resulting in severe sequelae and morbidity9. 
Mucosal lesions may cause airway obstruction and, in rare 
cases (approximately 1%), lead to death due to malnutrition, 
respiratory infection, and sepsis3,10,30. The disease usually 
affects patients older than 60 years11 and these patients are also 
more susceptible to the adverse effects of the drugs used to 
treat ATL12,13. 
The standard treatment for mucosal leishmaniasis (ML) 
defined by the World Health Organization (WHO), the Pan 
American Health Organization (PAHO), and the Brazilian 
Ministry of Health (MS) is a relatively toxic dose of N-methyl-
glucamine (N-MA) at 20 mg SbV/kg/day for 30 days by 
parenteral route. Therapeutic failure is also a concern and occurs 
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in 30%–42% of treated patients1,11,14. Antimony resistance is 
also possible and is a cause for concern, especially in India, 
although it has also been reported in other countries15. Second-
line treatment options include drugs such as amphotericin B and 
pentamidine; however, they are also administered by injection 
and have numerous severe adverse reactions16. 
Miltefosine (MILT) is an oral drug option used for the 
treatment of leishmaniasis. Some studies have demonstrated its 
efficacy for visceral leishmaniasis (VL) and CL17-20. However, 
the efficacy of this drug in ML is unknown. A previously 
published systematic review of the literature did not include any 
relevant studies on the use of MILT in ML and confirmed the 
lack of randomized clinical trials for this form of the disease21. 
The mechanism of action of MILT in Leishmania parasites 
is also unknown, although it is generally recognized that this 
medication affects lipid membranes by inhibiting cytochrome 
C oxidase, which is involved in mitochondrial function, as well 
as by inducing apoptosis, and producing immunomodulatory 
effects that improve phagocytosis by macrophages22,23. 
These mechanisms favor the use of MILT in the treatment 
of leishmaniasis because, in addition to its direct effects on 
parasites, it also modulates the body’s immune response against 
Leishmania22,23. 
The main objective of this study was to evaluate the efficacy 
and adverse events of MILT in ML compared to those of 
pentavalent antimonials in a pilot study with early and long-
term evaluation.
METHODS
The present study consists of a phase two, open-label, 
randomized clinical trial. Two parallel groups were compared.
Patient population
The study was conducted from January 2010 to December 
2016 at the Hospital Universitário de Brasília (HUB) in Brazil, 
to which patients are referred by primary care facilities for 
diagnostic confirmation of suspected cases of ATL. 
All patients with a confirmed diagnosis of ML were 
consecutively included after signing an informed consent form. 
The diagnosis of ML was made according to a previously 
described composite reference standard6,7. We included patients 
who had a clinical (the presence of any infiltration or ulceration 
in nasopharyngeal or oral structures) and an epidemiological 
history compatible with ML, in addition to parasite visualization 
(culture, direct examination, histopathology), or at least two of the 
following exams compatible with the diagnosis: Montenegro’s 
skin test, compatible histopathological infiltrate, and indirect 
immunofluorescence. The subgenus of the detected parasite 
was identified using polymerase chain reaction-restriction 
fragment length polymorphism (PCR-RFLP)6,7. Patients who 
were over 70 years old or less than 18 years old, who underwent 
specific treatment for leishmaniasis less than six months before 
recruitment, who showed any evidence of immunosuppression 
(e.g., HIV, immunosuppressive drugs), or who had any clinical 
condition that contraindicated the use of medications (e.g., 
pregnancy, renal failure, cardiopathy) were excluded.
A sample size of 40 patients was expected. This population 
was defined based on the availability of the tested drug, which 
is not yet commercially available in Brazil. 
Allocation and randomization
Patient allocation was made following a random assignment 
in fixed block sizes of four patients. A staff member, who was 
different from the principal investigator, randomly created a 
list containing ten groups of four patients. Two patients from 
each group were allocated to each block. The generated list was 
kept by an administrative employee who was not involved in 
either the intervention or the outcome measurements. Allocation 
started in June 2009 and finished in May 2012. 
Miltefosine group
The tested intervention consisted of the use of 1.3 to 2 mg/
kg/day (two capsules) of MILT for 28 days (Impavido® 50 
mg capsules, donated by Æterna Zentaris GmbH, Frankfurt, 
Germany). This dose was successfully used in some of our ML 
patients who were unresponsive to pentavalent antimonials and 
other drugs in a previous pilot study of this drug at our center 
(unpublished data). Patient weight varied from 43 to 75 kg, 
with a mean value of 60.6 kg. Although there is no current 
consensus regarding the dose of MILT for the treatment of New 
World leishmaniasis, the WHO suggests a dose of 2 mg/kg/day, 
while the PAHO suggests 1.5–2 mg/kg/day1,24. This drug is not 
commercialized in Brazil. 
Meglumine antimoniate group
The standard treatment was defined as the intravenous use of 
20 mg SbV/kg/day N-MA for 30 days (Glucantime® 81 mg/mL 
of antimony, 5-mL ampoule, Sanofi-Aventis, São Paulo, 
Brazil)1,9.
Outcomes
The main outcome was defined as complete re-epithelization 
and the absence of any inflammation of the lesion four years 
after the end of treatment. The patients were actively recruited 
at the hospital for clinical evaluation at 0, 30, 60, 90, and 
180 days, as well as every six months up to four years after 
treatment. Laboratory exams, clinical evaluation, and an 
electrocardiogram were performed weekly during treatment 
and immediately after the end of the treatment to monitor for 
adverse effects or laboratory abnormalities that would prompt 
treatment interruption. The adverse reactions that would lead to 
treatment interruption included, a corrected QT (QTc) interval 
of more than 450 ms, T-wave inversion, the presence of any 
arrhythmia by electrocardiogram, any alterations in serum 
urea or creatinine, and a greater than 2-fold alteration in the 
level of amylase, aspartate transaminase, alanine transaminase, 
hemogram, or electrolytes in relation to the reference levels 
adopted by the HUB. We also tested for the presence of any 
comorbidity that did not require exclusion from the study, 
such as controlled diabetes mellitus and hypertension. These 
evaluations were performed by at least one dermatologist and 
one otolaryngologist. The otolaryngologist evaluation included 
clinical evaluation and nasal fiber-optic examination.
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 Female 9 (50.0) 11 (55.0)
 Male 9 (50.0) 9 (45.0)
Comorbidities n (%) 3 (16.7) 8 (42.1)
Active cutaneous lesions n (%) 1 (5.6) 3 (15.0)
Age (years) 50.8 (SD=13.0) 61.2 (SD=11.3)
Disease time (months) 141.5 (SD=152.5) 112.4 (SD=133.3)
*SD: Standard deviation.
Statistical analysis
To estimate relative risks (RR) and 95% confidence intervals 
(CI) for each variable, a multiple analysis was conducted using 
Poisson regression with robust variance25. Significance level was 
set at 5%. All analyses were performed using SAS® 9.3 software 
(SAS Institute Inc., Cary, North Carolina, USA). 
Losses
With the aim of measuring efficacy, we performed two 
analyses: a per-protocol analysis including only patients 
who concluded treatment and excluding patients who lost 
the analyzed outcome, and an intention-to-treat-analysis, 
performed at 90 days and four years after treatment, in which 
any patient that missed a follow-up visit was considered a 
therapeutic failure. Treatment suspension was determined when 
patients received medical recommendations to stop taking the 
medication due to adverse events. Treatment abandonment was 
defined as patients who individually decided to stop treatment 
or follow-up visits independently of medical recommendations. 
Ethics
The study complied with the Declaration of Helsinki (1964 
and subsequent revisions). The study was approved by the Ethics 
Committee of the Faculty of Medicine, University of Brasilia 
(076/2008) and is registered in the clinicaltrials.gov database 
(NCT01377974). 
RESULTS
Basic characteristics and group comparisons
A total of 45 patients were screened for eligibility and of 
these, five patients did not meet the study criteria. Overall, 40 
patients were included in this study: 20 in the MILT group and 
20 in the N-MA group (Figure 1). The patients originated from 
a large area that included the Midwestern, Northwestern and 
Southwestern regions of Brazil; 46% were from the state of 
Goiás, 15% from Minas Gerais, 11% from Pará, and one patient 
from each of the following states: Bahia, Tocantins, Mato Grosso 
do Sul, Maranhão, Ceará, and the Federal District. Regarding 
clinical symptoms, 68% complained of nasal obstruction, 36% 
of nasal discharge, 23% of dyspnea, 13% of local pain, and 7% 
of dysphagia. Basic characteristics of the study population are 
described in Table 1. 
Regarding the localization of the lesions, of the 38 patients 
analyzed, 35 patients had lesions limited to the nose, one 
presented only oral lesions, and two patients presented lesions 
on the nasal, oral, and pharyngeal mucosa. Clinical examination 
showed erythema and nasal infiltration in 68% of cases, while 
60% revealed ulceration and septal perforation, 7% had soft 
palate infiltration and 2% had oropharyngeal fistulae or laryngeal 
infiltration. Four patients had concomitant mucosal and active skin 
lesions. Therefore, the majority of the patients had moderate to 
severe disease and were at least stage IV according to the clinical 
classification proposed by Lessa et al26. All patients resulted positive 
to the Leishmanin skin test (LST), and 55% of patients had positive 
indirect immunofluorescence titers at dilutions between 1:40 
and 1:80. Amastigote forms were found in the histopathological 
examinations of 6% of patients. PCR using kinetoplastid DNA 
(kDNA) from nasal swabs was positive in 58.82% of patients, 
where Leishmania (V.) braziliensis was detected. 
A difference between the two groups was found in relation 
to disease evolution time, which was 112.4 (standard deviation 
[SD] = 133.3) months in the MILT group and 141.5 (SD = 152.5) 
months in the N-MA group. Age also differed between the 
two groups: the mean age was 61.2 (SD = 11.3) years in the 
MILT group and 50.8 (SD =13.0) years in the N-MA group. 
In the N-MA group, three patients (16.7%) had comorbidities 
that did not result in exclusion (two patients with controlled 
hypertension and one with diabetes). In the MILT group, 
eight patients (42.1%) had comorbidities (three patients with 
controlled hypertension and five with diabetes). 
Losses
Considering the main endpoint of four years after the end of 
treatment, we had two losses in the MILT group and six losses in 
the N-MA group (Figure 1). In the MILT group, one patient had 
their treatment suspended due to abdominal pain and elevation 
of serum amylase at 231 U/L (reference values: 20–160 U/L), 
while the second patient abandoned clinical follow-up after 
treatment completion (Figure 1). In the N-MA group, two 
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patients did not complete the study due to treatment suspension 
related to an adverse prolonged corrected QTc interval. One of 
these patients had a QTc interval of 450 ms in the first week, 
while the other patient had a QTc interval of 500 ms at the 
end of the second week (RV: 350 to 450 ms). Furthermore, in 
the N-MA group, two patients declined to participate in the 
study after randomization prior to the first medication dose, 
alleging that the pentavalent antimonial side effects were too 
severe. Moreover, two additional patients also abandoned 
clinical follow-up after treatment completion. Upon analyzing 
the adverse reactions, the only significant differences found 
STUDY FLOW DIAGRAM
Assessed for eligibility (n=45)
Excluded (n=5)
 Not meeting inclusion criteria (n=5)
 Declined to participate (n=0)
 Other reasons (n=0)
Analysed (n=18)
 Excluded from analysis (Per-protocol 
analysis) (n=2)
Lost to follow-up (n=1)
Discontinued intervention- Abdominal pain and 
elevation of amylase levels (n=1)
Allocated to MILT (n=20)
 Received allocated intervention (n=20)
 Did not receive allocated intervention (n=0)
Lost to follow-up (n=2)
Discontinued intervention- Prolonged QTc 
interval (n=2)
Allocated to N-MA (n=20)
 Received allocated intervention (n=18)
 Did not receive allocated intervention 
(Declined prior to the first dose) (n=2)
Analysed (n=14)







FIGURE 1: Flow diagram of progress through the phases of the study. MILT: miltefosine group; N-MA: meglumine antimoniate group.
between the two groups were related to gastrointestinal effects 
(i.e., nausea, vomiting, and epigastric pain), which were more 
frequent in the MILT group (RR 2.97; 95% CI = 1.05–8.38). 
Among the cases of treatment suspension due to side effects, 
patients were treated with liposomal amphotericin B according 
to the Brazilian Ministry of Health protocols27. 
Per-protocol analysis
At the first endpoint 90 days after treatment, 11/12 and 7/10 
patients in the MILT and N-MA groups, respectively, were 
considered cured; while at 180-day follow-up after treatment, 
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11/12 and 9/10 patients in the MILT and N-MA groups, 
respectively, were considered cured. The multivariate analysis 
showed no difference in the cure rate the early follow-up at 90 
days after treatment (RR = 1.81; 95% CI = 0.88–3.74) (Table 2). 
Four years after the end of treatment, 16/18 and 12/14 
patients in the MILT and N-MA groups, respectively, were 
considered cured. Multivariate analysis revealed that patients 
treated with N-MA had a better cure rate (RR = 1.43; 95% 
CI = 1.25–1.64) (Table 2). Patients with co-morbidity also had 
a greater probability of cure (RR = 1.49; 95% CI = 1.13–1.97), 
as did patients with active cutaneous lesions (RR = 1.47; 95% 
CI = 1.08–1.99). 
Intention-to-treat analysis
Applying the multivariate model, 90 days after treatment, 
patients treated with MILT had a cure probability that was 
2.08 times greater than patients treated with N-MA (95% 
CI = 1.03–4.18); furthermore, the probability of cure was slightly 
higher in younger patients (95% CI = 0.95–1.00) (Table 2). 
Applying the proposed intention-to-treat analysis, four 
years after treatment, 16/20 and 12/20 patients in the MILT 
and N-MA groups, respectively, were considered cured. The 
MILT and N-MA groups had similar cure rates (RR = 0.66; 95% 
CI = 0.33–1.32) (Table 2). 
DISCUSSION
The development of a new therapeutic regimen for the 
treatment of ATL is considered a key strategy for public health1, 
since treatment represents the best modality to control the 
TABLE 2: Multivariate analysis in the per-protocol and in the intention-to-treat environment 90 days after treatment and four years after treatment. The 
representation of the variables followed the positive association
90 days after treatment
Per-protocol Intention-to-treat
RR (CI 95 %) RR (CI 95 %)
Male sex 1.93(0.77-4.84) 1.09(0.62-1.92)
No. comorbidities 0.97(0.36-2.63) 1.54(0.73-3.22)
No. active cutaneous lesions 1.63(0.91-2.94) 1.63(0.71-3.73)
Miltefosine group 1.81(0.88-3.74) 2.08(1.03-4.18)
No. treatment suspension 0.83(0.47-1.49) 3.67(0.8-16.66)
Age (years) 0.99(0.97-1.01) 0.98 (0.95-1.00)
Disease time (years) 1.00 (1.00–1.00) 1.00 (1.00–1.00)
4 years after treatment
Per-protocol Intention-to-treat
RR (CI 95 %) RR (CI 95 %)
 Female sex 1.01 (0.74–1.40) 1,01 (0,73–1,41)
Associated Comorbidities 1.49 (1.13–1.97) 1,01 (0,54–1,90)
Active cutaneous lesions 1.47 (1.08–1.99) 0,98 (0,54; 1,78)
Glucantime group 1.43 (1.25–1.64) 0,66 (0,33–1,32)
Treatment suspension 1.09 (0.90–1.32) 2,47 (0,86–7,04)
Age (years) 1.01 (1.00–1.01) 0,98 (0,96–1,00)
Disease time (years) 1.00 (1.00–1.00) 1,00 (1,00–1,00)
*RR: Relative risk; CI: Confidence interval.
disease. The high profile of adverse events and the necessity of 
parenteral administration for all first- and second-line drugs used 
in the treatment of ATL present major limitations for disease 
control. MILT is the only effective oral drug for the treatment 
of leishmaniasis17,28.
We performed a clinical trial in a center that is responsible 
for accepting referrals of ML patients in a broad area of Mid-
western Brazil. The majority of patients (72%) came from states 
were Leishmania (V.) braziliensis is the predominant species, 
and we were able to confirm Leishmania (V.) braziliensis as the 
causative species in most patients. Regarding clinical signs and 
symptoms, the population characteristics were similar to what 
has been described in previous studies and reviews29-31. 
Differences between the two experimental groups relative 
to subject characteristics, such as age and disease time, likely 
occurred due to chance. In addition, the absence of blinding 
or sham intervention may have weakened the allocation 
concealment. However, allocation through randomization is 
suggested when dealing with small groups, since it allows for 
groups of the same size32. Moreover, we used a multivariate 
model for the analysis, which can partially correct the effects 
of this imbalance. 
The presence of any co-morbidity that did not contraindicate 
the use of at least one of the interventions appeared to predict 
a better cure rate. Patients who had any type of incipient renal 
impairment, which is a frequent consequence of hypertension 
and diabetes, have a demonstrably slower metabolism of N-MA; 
accordingly, this metabolic impairment may also be true for 
MILT, as previous reports suggest33. 
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In the present study, the per-protocol analysis and the 
adjustment of the multivariate model showed that patients 
treated with N-MA had a probability of cure that was 1.43 
times higher than that of those treated with MILT (95% CI = 
1.25–1.64) (Table 2). Previously published data support N-MA 
as the gold standard for the treatment of ATL21. Additionally, 
in the per-protocol analysis, the presence of cutaneous lesions 
was associated with a better outcome. As ML is frequently 
the result of untreated cutaneous disease34, we believe that a 
plausible explanation for these results relies on the fact that 
patients with cutaneous lesions may present with a shorter 
disease duration. Consistently, three patients had fewer than six 
months of symptoms. Early leishmaniasis infections are known 
to respond better to treatment compared to chronic lesions33. 
We believe that in the intention-to-treat analysis, in which 
no differences were identified between MILT and N-MA 
(RR = 0.66; 95% CI = 0.33–1.32) (Table 2), the most relevant 
factors were not related to the ability of medications to kill 
Leishmania. Two patients declined to use N-MA after being 
randomized due to fear of adverse reactions35,36. Additionally, 
MILT tends to have only minor adverse effects (i.e., 
gastrointestinal effects). Although the multivariate models did 
not show a significant influence of treatment suspension on 
the main endpoint, suspension may be considered a serious 
limitation to the use of N-MA. In our study, 10% of patients 
had to stop treatment due to prolongation of their QTc interval. 
ML is an uncommon form of the disease. In a study of 2,820 
subjects in Brazil, approximately 5.3% of patients with CL had 
lesions on the nasal septum, palate or oropharynx37. Thus, ML 
studies designed to guide institutional therapeutic guidelines 
have been based on a limited number of patients 21. In this 
regard, our study is comparable in sample sizes to previous 
studies evaluating different therapies for ML31,38-40.
An important gap in the literature is related to the follow-up 
period. The primary endpoints of most ML studies vary between 
150 days and 12 months31,38-40. However, different case series 
have shown a high relapse rate of ML, varying between 17% 
and 33.8%41-44 and relapses of ML tend to occur one year after 
treatment completion43. Thus, we were able to evaluate these 
patients for an extended period of time after therapy, partially 
overcoming the limitations of previous studies. In contrast to CL, 
ML rarely resolves spontaneously45,46; therefore, it seems plausible 
that setting the primary endpoint after four years of treatment 
is indicative not only of relapse rates but also of initial cure 
rates. 
According to the last WHO expert committee report on the 
control of leishmaniasis1, MILT is an option for the treatment 
of ML; however, this recommendation was based on an open-
label, non-randomized trial from Bolivia in which patients were 
followed for 12 months after the completion of therapy46,47. 
We believe that our study characteristics (i.e., allocation 
through randomization, inclusion and exclusion criteria, follow-
up time, disease form, diagnostic methods, Leishmania species, 
and patient origin) were adequate to deal with the study question. 
In the last systematic review on leishmaniasis treatment, there 
were only four studies on ML in the Americas21.
Previously published studies have reported that the management 
of clinical trials in ATL is extremely difficult48. The disease tends 
to affect people with economic difficulties, resulting in mobility 
issues and, ultimately results in poor adherence to treatment, which 
also occurred in the present trial. This fact makes the intention-to-
treat analysis an important strategy for avoiding overly optimistic 
results taken from a per-protocol analysis. In a recent pilot study 
in Argentina, Bustos et al. did not find a difference in efficacy 
between patients treated with a higher dose of MILT (2.5 to 
3.3 mg/kg/daily) and those treated with N-MA49. MILT dosing, 
especially in children, is frequently a subject of discussion and 
the pharmacokinetics of the drug are still being investigated50. 
Some evidence has suggested that MILT dosing should always 
be determined according to body weight50. In contrast to what 
we have observed regarding VL, regulatory institutions have no 
standardized MILT dose for ML treatment1,24. In this study, the 
MILT dosage used in some patients could also explain its lower 
performance when compared to N-MA in this preliminary analysis. 
Conversely, these doses have been already used with good results 
in clinical trials involving patients with VL and CL. Thus, we 
selected the 1.3–2 mg/kg/day dosage based on the good results of 
a previous pilot study from our institution that included patients 
switching to MILT after the failure of other conventional options. 
Limitations
The cure rate was likely underestimated due to the number 
of patients lost to follow-up. As HUB is the main regional 
referral hospital for ATL in a region where medical support is 
scarce, it has been reported that many patients only return for 
consultations when relapse or treatment failure occurs33. Patients 
older than 70 years or younger than 18 years were not included 
in the study; additionally, patients with severe heart or kidney 
disease were also not included. Consequently, we are not able 
to provide data regarding patients with these characteristics51. 
Another limitation of this study is that no comparison between 
body weight and applied dosage was performed. It is also 
important to stress that the study protocol was approved 
before the Brazilian Ministry of Health’s new guidelines were 
published, which recommend that patients aged 50 years or 
more be treated with liposomal amphotericin B9. 
Conclusions
This study represents a significant advancement in the field, 
since studies for ML are frequently limited by a small number of 
patients, absence of a control group, or low quality of evidence52. 
Considering that the intention-to-treat analysis is better suited 
to the effects of interventions in daily practice53, we consider 
MILT an important option for the treatment of ML, in line with 
other indications in other forms of leishmaniasis. The range of 
adverse effects seems to be more easily managed than the effects 
of classical treatments, resulting in improved patient safety and 
well-being. Nevertheless, comparison of MILT to N-MA in ML 
should be evaluated in a larger patient population.
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